Marvell收购Lumentum重塑估值逻辑
Marvell收购Lumentum重塑估值逻辑
I'll start with the current quote, the recent price path, and the news on the target-price cuts.
Conclusion: The 10.69% gain on Nov 9 was mostly a rebound in Marvell's stock, which now sets the value of Lumentum's pending all-stock takeover. The target cuts track the same deal, not a deterioration in Lumentum's operations. Recent results and guidance were strong. The stock is now a proxy for Marvell's share price and for whether the deal clears shareholder and Chinese regulatory hurdles, so those are what investors should watch.
Data as of: Nov 9, 2026 close (16:00 ET), which is Nov 10 in Shanghai. Quote and chart data are from Driven; news and filings are from the sources listed below.
1. Why the signals conflict
- The deal reset the valuation anchor. On Nov 2 Marvell agreed to buy Lumentum for 4.500 Marvell shares per Lumentum share, a headline value of about $1,132 (a 23.9% premium) and an implied $115B enterprise value. Because the ratio is fixed, every $1 move in Marvell changes the package by $4.50 per share (). Marvell closed at on Nov 9, up from . At that price the package is worth per Lumentum share, which is the $1,132 headline.
- Lumentum's price fell with the deal. The stock closed at on Nov 2, down from on Oct 30. It then fell to on Nov 5, a drop. Shareholder opposition, dilution concerns, and a long closing timeline drove the selloff. Critics included TD Cowen, BofA, Needham and Cantor Fitzgerald, and BofA's Vivek Arya questioned whether about $1B of projected cost savings could offset Marvell's roughly 50% share-count increase ().
- The rebound is a deal-spread trade. Lumentum rose from the Nov 5 close to on Nov 9, when it gained from . Marvell's recovery narrowed the gap to the exchange ratio, and cited that as the main driver alongside the earnings beat. Quiver's intraday piece put the gain at and attributed it to takeover speculation, but its description of "advanced talks" predates the Nov 2 announcement, so I treat it as low-reliability.
- Target cuts and upgrades are split. TD Cowen cut its target from and kept Hold (). Bernstein cut to and kept Outperform. Raymond James upgraded to Strong Buy with a target. Several targets were set against the deal package, so they are a mix of valuation views and deal-price views.
2. Recent results and outlook
- Fiscal Q1 2027 (ended Sep 26) revenue was , up from . Non-GAAP EPS was and GAAP EPS was $3.54 ().
- Q2 guidance is revenue of , non-GAAP operating margin of , and non-GAAP EPS of . The midpoint of implies sequential growth.
- The company cites a second major NPO/CPO design win with purchase commitments exceeding $5 billion, and it expects optical circuit switches to become a multi-billion-dollar annual revenue line.
- Cash was at quarter end, down in the quarter. I did not verify the cause from the sources I read.
- The fiscal Q4 2026 GAAP net loss was $7.2B ($84.65 per share), so GAAP and non-GAAP figures diverge sharply. The reason for that loss is not in the material I reviewed.
3. Valuation
- At , market cap is on 90.7M shares.
- On the Q2 EPS midpoint annualized, the P/E is . On Q1 annualized, it is . Both are run-rate estimates, not reported trailing multiples.
- Cash of about is a small part of the price.
- The deal package trades at a gross spread to the current price, which is the market's rough estimate of deal risk and timing (closing targeted for the first half of 2028).
- The stock's 50-day SMA is and the 14-day RSI is , so it remains well below its recent trend.
- MarketBeat's consensus average target of was compiled before the cuts and is stale.
4. What investors should watch
- Marvell's share price. Each $1 move changes the package by $4.50 per Lumentum share. Lumentum's price will track Marvell until the deal closes or breaks.
- Shareholder votes and the bid's terms. Lumentum holders have pushed back, and William Blair flagged the risk of outright rejection if Marvell keeps falling (). Watch for any cash component or revised ratio.
- China's regulatory review. Cantor's C.J. Muse called it the biggest uncertainty, and Counterpoint noted possible US restrictions on Chinese optical-transceiver imports ().
- Q2 delivery. Revenue of $1.575B–$1.625B and a margin above 45% are the operating checks. A miss would weaken the standalone case that analysts such as Raymond James use to support their targets.
- Conversion of the $5B+ commitments into shipments and the optical-switch ramp.
- Forecast disagreement. Invezz-syndicated analyst estimates of the 2027 optical-transceiver market range from $47B (TD Cowen) to about $100B bottom-up (). The gap matters because it drives how attractive the acquisition looks.
Data caveats
- The sources disagree on TD Cowen's target. MarketBeat reports $820→$685, while NeoTeo reports $350→$175. I used MarketBeat's figure and did not resolve the discrepancy.
- One source says Lumentum rose 6.6% on Friday. The chart's close-to-close move was about 5.7%, so I used the chart.
- Insider activity: Quiver reports 77 insider sales and no purchases over six months. Quiver is a secondary aggregator, so I treat this as context only.
Sources
- Driven quote, Nov 9, 2026 16:00 ET: LITE and MRVL ()
- Driven daily adjusted closes and 50-day SMA / 14-day RSI, Aug 3–Nov 9, 2026 ()
- Lumentum fiscal Q1 2027 results release, Nov 2, 2026 (Business Wire)
- Q2 guidance coverage (Nasdaq / Business Wire search results)
- Marvell–Lumentum deal terms and valuation analysis, Nov 8, 2026 (NeoTeo)
- Shareholder opposition and analyst reactions, Nov 4, 2026 (TALi News)
- TD Cowen target cut, Nov 3, 2026 (MarketBeat)
- Bernstein cut and Raymond James upgrade, Nov 9, 2026 (ad-hoc-news)
- Intraday move attribution, Nov 9, 2026 (low reliability) (Quiver Quantitative)
- Derived figures: